Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PerkinElmer Inc.
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Birmingham, UK-based The Binding Site and its 1,100 employees will now fall under Thermo Fisher’s expanding umbrella.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Technologies
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Analytica of Branford, Inc.
- Arnel Inc.
- BioLegend, Inc.
- Haoyuan Biotech Co. Ltd.
- Immunodiagnostic Systems Holdings PLC
- Opto Technology, Inc.
- Perten Instruments
- SYM-BIO Lifescience
- Tulip Diagnostics Private Limited
- Wallac Oy
- Vanadis Diagnostics, AB
- Oxford Immunotec Global PLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.